WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558202
CAS#: 6041-00-5
Description: Kefton-2 is bioactive chemical.
Hodoodo Cat#: H558202
Name: Kefton-2
CAS#: 6041-00-5
Chemical Formula: C31H40O2
Exact Mass: 444.30
Molecular Weight: 444.660
Elemental Analysis: C, 83.74; H, 9.07; O, 7.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Kefton2; Kefton-2; Kefton 2;
IUPAC/Chemical Name: 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-
InChi Key: DKHGMERMDICWDU-GHDNBGIDSA-N
InChi Code: InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
SMILES Code: O=C1C(C)=C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)C(C2=C1C=CC=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 444.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Iwamoto J. Vitamin K₂ therapy for postmenopausal osteoporosis. Nutrients. 2014 May 16;6(5):1971-80. doi: 10.3390/nu6051971. Review. PubMed PMID: 24841104; PubMed Central PMCID: PMC4042573.
2: Inoue T, Dohara Y, Sugihara K, Fujisaki S, Nagatani Y. [Intravenous Kefton-2, a hemostatic, in oral surgery]. Shikai Tenbo. 1980 Nov;56(5):871-5. Japanese. PubMed PMID: 6942517.
3: Shearer MJ, Newman P. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 2014 Mar;55(3):345-62. doi: 10.1194/jlr.R045559. Epub 2014 Jan 31. Review. PubMed PMID: 24489112; PubMed Central PMCID: PMC3934721.
4: Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging. 2014;9:121-7. doi: 10.2147/CIA.S54107. Epub 2014 Jan 8. PubMed PMID: 24426779; PubMed Central PMCID: PMC3890406.
5: Avior Y, Levy G, Zimerman M, Kitsberg D, Schwartz R, Sadeh R, Moussaieff A, Cohen M, Itskovitz-Eldor J, Nahmias Y. Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes. Hepatology. 2015 Jul;62(1):265-78. doi: 10.1002/hep.27803. Epub 2015 Apr 22. PubMed PMID: 25808545.
6: Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S. Efficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases. Intern Med. 2016;55(15):1997-2003. doi: 10.2169/internalmedicine.55.6230. Epub 2016 Aug 1. PubMed PMID: 27477405.
7: Okano T. A New Horizon in Vitamin K Research. Yakugaku Zasshi. 2016;136(8):1141-59. doi: 10.1248/yakushi.16-00014. Review. Japanese. PubMed PMID: 27477733.
8: Schumacher MM, Jun DJ, Jo Y, Seemann J, DeBose-Boyd RA. Geranylgeranyl-regulated transport of the prenyltransferase UBIAD1 between membranes of the ER and Golgi. J Lipid Res. 2016 Jul;57(7):1286-99. doi: 10.1194/jlr.M068759. Epub 2016 Apr 27. Erratum in: J Lipid Res. 2016 Aug;57(8):1599. PubMed PMID: 27121042; PubMed Central PMCID: PMC4918857.
9: Guralp O, Erel CT. Effects of vitamin K in postmenopausal women: mini review. Maturitas. 2014 Mar;77(3):294-9. doi: 10.1016/j.maturitas.2013.11.002. Epub 2013 Nov 27. Review. PubMed PMID: 24342502.
10: Gentili A, Cafolla A, Gasperi T, Bellante S, Caretti F, Curini R, Fernández VP. Rapid, high performance method for the determination of vitamin K(1), menaquinone-4 and vitamin K(1) 2,3-epoxide in human serum and plasma using liquid chromatography-hybrid quadrupole linear ion trap mass spectrometry. J Chromatogr A. 2014 Apr 18;1338:102-10. doi: 10.1016/j.chroma.2014.02.065. Epub 2014 Feb 28. PubMed PMID: 24630057.
11: Tsugawa N. [Clinical Pharmacokinetics of Active Vitamin D3 and its derivatives, and Vitamin K2(Menatetrenone).]. Clin Calcium. 2016;26(11):1547-1558. Japanese. PubMed PMID: 27777388.
12: Ferland G. Vitamin K and brain function. Semin Thromb Hemost. 2013 Nov;39(8):849-55. doi: 10.1055/s-0033-1357481. Epub 2013 Oct 9. Review. PubMed PMID: 24108469.
13: Iwamoto J, Sato Y. Menatetrenone for the treatment of osteoporosis. Expert Opin Pharmacother. 2013 Mar;14(4):449-58. doi: 10.1517/14656566.2013.763796. Epub 2013 Jan 25. Review. PubMed PMID: 23346882.
14: Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012 Nov 12;11:93. doi: 10.1186/1475-2891-11-93. PubMed PMID: 23140417; PubMed Central PMCID: PMC3502319.
15: Iwamoto J, Seki A, Sato Y, Matsumoto H. Vitamin K(2) improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int. 2012 Jan;90(1):50-9. doi: 10.1007/s00223-011-9548-3. Epub 2011 Nov 13. PubMed PMID: 22080166.
16: Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27. PubMed PMID: 25747538.
17: Wu WJ, Kim MS, Ahn BY. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption. Food Funct. 2015 Oct;6(10):3351-8. doi: 10.1039/c5fo00544b. PubMed PMID: 26267519.
18: Kiely M, Hodgins SJ, Merrigan BA, Tormey S, Kiely PA, O'Connor EM. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutr Res. 2015 Aug;35(8):736-43. doi: 10.1016/j.nutres.2015.05.014. Epub 2015 May 30. PubMed PMID: 26082424.
19: McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013 May;83(5):835-44. doi: 10.1038/ki.2012.477. Epub 2013 Jan 23. PubMed PMID: 23344475.
20: Wyskida K, Żak-Gołąb A, Łabuzek K, Suchy D, Ficek R, Pośpiech K, Olszanecka-Glinianowicz M, Okopień B, Więcek A, Chudek J. Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. Clin Biochem. 2015 Dec;48(18):1246-51. doi: 10.1016/j.clinbiochem.2015.08.011. Epub 2015 Aug 15. PubMed PMID: 26282719.